For the Inventor, By the Inventor

Enter assignee name

Kyowa Hakko Kirin Co., Limited

USPTO Granted Patents = 272

CIPO Patents = 39

EPO Patents = 130

Trademarks = 22

Forward Citations = 1,571

Loading Chart...

Loading Chart...

456 inventors (with patents filed for the assignee):

Kazuyasu Nakamura (44 out of 68 patents)

Motoo Yamasaki (35 out of 77 patents)

Yutaka Kanda (34 out of 64 patents)

4. Emi Hosaka (31 out of 39 patents)

5. Nobuo Hanai (30 out of 81 patents)

6. Kenya Shitara (25 out of 56 patents)

7. Kazuhisa Uchida (24 out of 30 patents)

8. Toyohide Shinkawa (24 out of 29 patents)

9. Naoko Yamane (24 out of 28 patents)

10. Mitsuo Satoh (19 out of 24 patents)

11. Kazuma Tomizuka (18 out of 29 patents)

12. Tsuguo Kubota (16 out of 19 patents)

13. Rinpei Niwa (16 out of 20 patents)

14. Kazuya Yamano (15 out of 20 patents)

15. Isao Ishida (14 out of 29 patents)

Core Competencies:

Antibody Composition

Cationic Lipid

Oligonucleotide

Therapeutic Agent

Human Artificial Chromosome

RNAi Pharmaceutical Composition

Lipid Nanoparticles

Transgenic Rodents

Protein Production Method

Cancer Treatment

Wnt Signaling Inhibitor

Chemokine Receptor Antagonists

272 patents: Sort by Forward Citations

1. 11117963 - Antibody which binds to myelin oligodendrocyte glycoprotein (2021-09-14),

2. 10548891 - Nitrogen-containing heterocyclic compound having inhibitory effect on production of kynurenine (2020-02-04),

3. 10525138 - Compound as cationic lipid (2020-01-07),

4. 10500158 - Cationic lipid (2019-12-10),

5. 10448622 - Human artificial chromosome containing human antibody lambda light chain gene and non-human animal containing the human artificial chromosome capable of genetic transmission (2019-10-22),

6. 10407440 - Therapeutic agent for motor disorders (2019-09-10),

7. 10378011 - Oligonucleotide (2019-08-13),

8. 10358671 - Protein production method (2019-07-23),

9. 10350194 - Pharmaceutical composition containing an arylalkylamine compound (2019-07-16),

10. 10342819 - Oligonucleotide having non-natural nucleotide at 5'-terminal thereof (2019-07-09),

11. 10342758 - Cationic lipid (2019-07-09),

12. 10294302 - Therapeutic method and medicament for HTLV-1 associated myelopathy (2019-05-21),

13. 10233475 - Antibody composition-producing cell (2019-03-19),

14. 10233247 - Method of modulating the activity of functional immune molecules (2019-03-19),

15. 10233246 - Antibody and antibody fragment introduced new modification sites (2019-03-19),

Kyowa Hakko Kirin Co., Ltd. is a global pharmaceutical company that develops innovative drugs and biologics, with a focus on oncology, nephrology, immunology, and other therapeutic areas. With a commitment to improving the health and well-being of people worldwide, Kyowa Hakko Kirin strives to provide high-quality and affordable medications. Through continuous research and development, they aim to contribute to medical advancements and address unmet medical needs.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Jan 6 2026

272 Patents

#253 in Tokyo

#551 in Japan

#3,129 in the World

Kyowa Hakko Kirin Co., Limited

Forward Citations = 1,571

456 inventors:

Kazuyasu Nakamura (44 out of 68 patents)

Motoo Yamasaki (35 out of 77 patents)

Yutaka Kanda (34 out of 64 patents)

4. Emi Hosaka (31 out of 39 patents)

5. Nobuo Hanai (30 out of 81 patents)

Please report any incorrect information to support@idiyas.com

Loading…